TY - JOUR
T1 - A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II-IIIA non-small cell lung cancer
T2 - Study protocol for a randomized controlled trial
AU - Saka, Hideo
AU - Kitagawa, Chiyoe
AU - Ichinose, Yukito
AU - Takenoyama, Mitsuhiro
AU - Ibata, Hidenori
AU - Kato, Tatsuo
AU - Takami, Koji
AU - Yamashita, Motohiro
AU - Maeda, Tadashi
AU - Takeo, Sadanori
AU - Ueda, Hitoshi
AU - Okabayashi, Kan
AU - Nagashima, Seiji
AU - Oka, Tadayuki
AU - Kouso, Hidenori
AU - Fukuyama, Seiichi
AU - Yoshimoto, Kentaro
AU - Shimokawa, Mototsugu
AU - Saito, Akiko M.
AU - Ito, Suminobu
N1 - Publisher Copyright:
© 2017 The Author(s).
PY - 2017/9/15
Y1 - 2017/9/15
N2 - Background: As the toxicity associated with the α-GalCer-pulsed dendritic cell (DC) therapy could be considered to be negligible, its addition to postoperative adjuvant chemotherapy would be expected to greatly improve the therapeutic effect, and could result in prolonged survival. The aim of the present study is to compare the therapeutic efficacy of alpha-galactosylceramide-pulsed DC therapy in patients who have undergone a complete resection of stage II-IIIA non-small-cell lung cancer (NSCLC) followed by postoperative adjuvant therapy with cisplatin plus vinorelbine, to that in patients who did not receive additional treatment (surgical resection plus postoperative adjuvant chemotherapy only). Methods: Subsequent to the complete resection of NSCLC, followed by the administration of cisplatin plus vinorelbine dual-agent combination adjuvant chemotherapy, patients who satisfy the inclusion criteria will be randomly allocated to either the α-GalCer-pulsed DC immune therapy group, or the standard treatment group. In total, 56 patients will be included in the study. The primary endpoint is recurrence-free survival, and the secondary endpoints are natural killer T-cell-specific immune response, the frequency of toxic effects and safety, and overall survival. Discussion: In order to determine the efficacy of α-GalCer-pulsed DC therapy, the present study compares patients with stage II-III NSCLC who underwent complete surgical resection followed by postoperative adjuvant therapy with cisplatin plus vinorelbine, to those who did not receive additional treatment (surgical resection plus postoperative adjuvant chemotherapy only). Trial registration: UMIN000010386 ( R000012145 ). Registered on 1 April 2013. UMIN-CTR is officially recognized as a registration site which satisfies ICMJE criteria.
AB - Background: As the toxicity associated with the α-GalCer-pulsed dendritic cell (DC) therapy could be considered to be negligible, its addition to postoperative adjuvant chemotherapy would be expected to greatly improve the therapeutic effect, and could result in prolonged survival. The aim of the present study is to compare the therapeutic efficacy of alpha-galactosylceramide-pulsed DC therapy in patients who have undergone a complete resection of stage II-IIIA non-small-cell lung cancer (NSCLC) followed by postoperative adjuvant therapy with cisplatin plus vinorelbine, to that in patients who did not receive additional treatment (surgical resection plus postoperative adjuvant chemotherapy only). Methods: Subsequent to the complete resection of NSCLC, followed by the administration of cisplatin plus vinorelbine dual-agent combination adjuvant chemotherapy, patients who satisfy the inclusion criteria will be randomly allocated to either the α-GalCer-pulsed DC immune therapy group, or the standard treatment group. In total, 56 patients will be included in the study. The primary endpoint is recurrence-free survival, and the secondary endpoints are natural killer T-cell-specific immune response, the frequency of toxic effects and safety, and overall survival. Discussion: In order to determine the efficacy of α-GalCer-pulsed DC therapy, the present study compares patients with stage II-III NSCLC who underwent complete surgical resection followed by postoperative adjuvant therapy with cisplatin plus vinorelbine, to those who did not receive additional treatment (surgical resection plus postoperative adjuvant chemotherapy only). Trial registration: UMIN000010386 ( R000012145 ). Registered on 1 April 2013. UMIN-CTR is officially recognized as a registration site which satisfies ICMJE criteria.
KW - Immunotherapy
KW - Non-small cell lung cancer
KW - Phase II
UR - http://www.scopus.com/inward/record.url?scp=85029497236&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029497236&partnerID=8YFLogxK
U2 - 10.1186/s13063-017-2103-4
DO - 10.1186/s13063-017-2103-4
M3 - Article
C2 - 28915900
AN - SCOPUS:85029497236
SN - 1745-6215
VL - 18
JO - Trials
JF - Trials
IS - 1
M1 - 429
ER -
